Peptide Research
Sermorelin Research: GHRH(1-29), Pituitary Signaling & GH Release
Oct
GHRH Research • Research Use Only
Sermorelin is the amidated 1-29 fragment of growth-hormone-releasing hormone and is widely used as a research tool for studying pituitary somatotroph signaling, GHRH-receptor activation, and the dynamics of growth-hormone release.
What Is Sermorelin?
Sermorelin corresponds to the biologically active N-terminal 29-amino-acid region of human GHRH. Research established that GHRH(1-29)-NH2 retains strong growth-hormone-releasing activity, making it useful for studying receptor pharmacology without the full 44-amino-acid native peptide.
A human study comparing GHRH fragments found that GHRH(1-29)-NH2 retained substantial activity in stimulating GH release. See Growth hormone responses to GHRH(1-29)-NH2.
GHRH Receptor and cAMP Signaling
The GHRH receptor is expressed on pituitary somatotroph cells. Receptor activation is associated with Gs-protein signaling, adenylyl cyclase, cAMP generation, and downstream events involved in GH synthesis and secretion. Researchers can measure secretory responses as well as receptor desensitization, intracellular signaling, and transcript-level changes.
Why Pulse Timing Matters
GH physiology is pulsatile. That makes sampling design important: peak response, time-to-peak, decay, total area under the curve, and baseline secretion can tell different stories. Dose-response research with GHRH(1-29) has shown that the magnitude and duration of secretory responses can vary with experimental exposure. See Low-dose growth hormone-releasing hormone tests.
Sermorelin vs. Tesamorelin
Both peptides target the GHRH receptor, but their structures and stability differ. Tesamorelin is based on the longer GHRH sequence and includes a stabilizing modification. Sermorelin is a shorter 1-29 fragment. Comparing them can help researchers examine how peptide length and stability influence receptor activation and secretory kinetics.
Sermorelin vs. GHRP-2 and GHRP-6
GHRP-2 and GHRP-6 primarily activate the growth-hormone secretagogue receptor (GHS-R1a), a receptor system associated with ghrelin biology. Sermorelin instead models the GHRH receptor pathway. These two systems can converge on GH release through different upstream receptors.
Sermorelin 5mg at Revolt Peptides
See the Sermorelin 5mg research product page. Related research materials include Tesamorelin 10mg and Ipamorelin/CJC No DAC 5mg/5mg.
Common Laboratory Endpoints
- GHRH-receptor activation and cAMP signaling
- GH release and secretory kinetics
- Somatotroph responsiveness and receptor desensitization
- Comparisons with stabilized GHRH analogues
- Interactions between GHRH and GHS-R signaling pathways
Evidence Limits
Sermorelin has a long history as a research and diagnostic peptide, but mechanistic findings should remain tied to the exact experimental system. This article does not provide administration or clinical-use guidance.
Sermorelin FAQ
What does “1-29” mean?
It refers to the first 29 amino acids of the human GHRH sequence, which contain the core receptor-active region.
Is sermorelin a ghrelin-receptor agonist?
No. Its principal research target is the GHRH receptor.
Browse the Research Journal for more peptide signaling articles.
Research Use Only. Not intended for human or veterinary use.
